Success Metrics

Active Trials
2(40%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_3
3
60%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Not yet recruiting3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 33 (75.0%)

Trials by Status

not_yet_recruiting360%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
not_yet_recruitingphase_3

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

NCT07383116
not_yet_recruitingphase_3

JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

NCT07154368
recruitingphase_2

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

NCT06969027
recruiting

Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir

NCT06399926
not_yet_recruitingphase_3

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

NCT06380348

Clinical Trials (5)

Showing 5 of 5 trials
NCT07383116Phase 3

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Not Yet Recruiting
NCT07154368Phase 3

JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

Not Yet Recruiting
NCT06969027Phase 2

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

Recruiting
NCT06399926

Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir

Recruiting
NCT06380348Phase 3

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5